Risk factors and current management of venous thromboembolism in patients with primary immune thrombocytopenic purpura.
- 7 February 2021
- journal article
- letter
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 86, 121-123
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Anticoagulation in thrombocytopenic patients with hematological malignancy: A multinational clinical vignette-based experimentEuropean Journal of Internal Medicine, 2020
- American Society of Hematology 2019 guidelines for immune thrombocytopeniaBlood Advances, 2019
- Thrombopoietin receptor agonists: ten years laterHaematologica, 2019
- Splenectomy is associated with a higher risk for venous thromboembolism: A prospective cohort studyInternational Journal of Surgery, 2015
- Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic reviewJournal of Thrombosis and Haemostasis, 2014
- Increased procoagulant cell-derived microparticles (C-MP) in splenectomized patients with ITPThrombosis Research, 2008
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005